5 Best Oil Service Stocks To Own Right Now

It's no secret that capital spending budgets are falling at oil companies across the globe, but that's not the case for this company, writes MoneyShow's Jim Jubak, who points out the efficiency measures and new technology products responsible for much of its success.

Everyone knows that capital spending budgets at the world's oil companies are falling.

But it just doesn't seem to matter for Schlumberger (SLB). Schlumberger is a member of my Jubak's Picks portfolio.

On January 17, the oil services and technology company reported fourth quarter earnings of $1.35 a share, beating Wall Street estimates by two cents a share. Earnings grew by 29.8% year over year.

Revenue climbed 7.4% year over year to $11.91 billion. That was slightly below the $11.98 projected by Wall Street.

I think you can tell what's going on at Schlumberger simply by taking a glance at those earnings and revenue growth rates. Revenue growth is indeed sluggish in the oil field. But Schlumberger's margins are climbing, thanks to efficiencies at the company and, especially, thanks to its years of investment in oil field technologies.

Top 5 Railroad Stocks To Buy Right Now: LMP Real Estate Income Fund Inc (RIT)

LMP Real Estate Income Fund Inc. (the Fund) is a non-diversified, closed-end management investment company. The Fund�� primary investment objective is to provide high current income. Its secondary investment objective is capital appreciation. Legg Mason Partners Fund Advisor, LLC (LMPFA) is the Fund�� investment manager and AEW Management and Advisors, L.P. (AEW) is the Fund�� subadviser. LMPFA is a wholly owned subsidiary of Legg Mason, Inc.

The Fund invests in securities related to the real estate industry. Its portfolio includes common stocks, preferred stocks and short-term investments. The Fund invests in sectors, such as office, healthcare, diversified, apartments, industrial, shopping centers, home financing, lodging/resorts, regional malls and specialty.

Advisors' Opinion:

• [By Joe Eqcome]

  Actionable Items:

  Highest Positive Spread: Nuveen Mortgage Opportunity Term Fund (JLS)Focus Stock: LMP Real Estate Income Fund (RIT)Last Week's Focus Stock: ASA Gold and Precious Metals (ASA)

  ECB cuts its rates: The European Central Bank (ECB) will cut its benchmark rate a quarter-of-a-point to 0.5%.

• [By GURUFOCUS]

  Special Purpose Funds- Eaton Vance Tax-Adv. Global Dividend Oppor. Fund (ETO) | Yield: 7.3%
  - The Gabelli Global Utility & Income Trust (GLU) | Yield: 6.2%
  - Pimco Global Stocksplus Income Fund (PGP) | Yield: 9.5%
  - LMP Real Estate Income Fund Inc. (RIT) | Yield: 7.0%

5 Best Oil Service Stocks To Own Right Now: Shoe Carnival Inc (SCVL)

Shoe Carnival, Inc. is a family footwear retailer. The Company offers customers an assortment of dress, casual and athletic footwear for men, women and children with emphasis on national and regional name brands. The Company�� stores averaged approximately 10,800 square feet, ranging in size from 6,000 to 26,500 square feet. As of January 28, 2012, the Company operated 327 stores located across 32 states and offered online shopping at www.shoecarnival.com. Its average store carries approximately 28,500 pairs of shoes in four general categories, such as men��, women��, children�� and athletics. In addition to footwear, its stores carry selected accessory items complementary to the sale of footwear.

The Company operates a single 410,000 square foot distribution center located in Evansville, Indiana. Women��, men�� and children�� non-athletic footwear categories are further divided into dress, casual, sport, sandals and boots. It classifies athletic shoes by functionality, such as running, basketball or fitness shoes. During the fiscal year ended January 28, 2012 (fiscal 2011), athletic styles, including children�� sizes, have represented approximately 50% of its footwear sales.

Advisors' Opinion:

• [By Jeremy Bowman]

  What: Shares of Shoe Carnival (NASDAQ: SCVL  ) were partying on Friday, gaining as much as 10% after reporting a strong first quarter.

  So what: The shoe-selling chain turned in a per-share profit of $0.47, $0.07 ahead of the analyst consensus, while revenue crept up 4.3% thanks to an 8% increase in store count over the year. Same-store sales, however, decreased 0.8%, perhaps indicating organic weakness in the retailer. CEO Cliff Sifford noted "the colder, wetter weather" made the quarter "challenging," as many other retailers have said this season. Better weather in April improved the sales trajectory and helped the company beat expectations. Its outlook for the current quarter was in line with estimates with an EPS of $0.26-$0.30 and same-stores increasing 3-5%.

• [By Lauren Pollock]

  Shoe Carnival Inc.'s(SCVL) fiscal third-quarter earnings slid 11%, with revenue declining due to an unfavorable calendar shift from the previous year.

5 Best Oil Service Stocks To Own Right Now: Genomma Lab Internacional SAB de CV (LABB.MX)

Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company�� product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. Advisors' Opinion:

• [By Ben Levisohn]

  He then took a deep dive into Genomma Lab�(LABB.MX), a Mexican producer of over-the counter pharmaceuticals, generic drugs, and personal care products. Now, I’m sitting with a Chromebook in a large auditorium, so I hope I’ve captured the essence of his argument.

5 Best Oil Service Stocks To Own Right Now: Interleukin Genetics Inc (ILIU.PK)

Interleukin Genetics, Inc., incorporated on March 28, 2000, is a personalized health company, which develops genetic tests to provide information to manage health and specific health risks. The Company�� business focuses on personalized health, by providing genetic tests with clinical value. Its tests are made available through marketing partners or directly to end users. The Company's primary business focus and strategy is to continue the Company's commercialization efforts with its PST genetic test. In addition, the Company plans to continue to develop and sells tests for its own business needs under the Inherent Health brand.

The Company's genetic tests that are being commercialized includes PST is a genetic test, which analyzes genetic variations associated with inflammation and identifies individuals who are at increased risk for more severe periodontal disease; Weight Management Genetic Test determines whether a low fat, low carbohydrate or balanced diet may normal or vigorous exercise, which is needed to lose existing body fat; Bone Health Genetic Test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis; Heart Health Genetic Test is designed to identify genetic predisposition to excess inflammation, which is a risk factor for heart attack, and Wellness Select Genetic Test allows buyers to purchase any combination of Inherent Health genetic tests at a discounted price. The Company is also focusing its genetic test development efforts on the development of an Osteoarthritis, or OA, genetic test to identify individuals at increased risk for severe OA.

Genetic Test for Risk of Periodontal Disease

PST is a genetic test that analyzes genetic variations associated with inflammation and identifies individuals who are at increased risk for more severe periodontal disease. The PST genetic test identifies specific polymorphisms (genetic variations) in genes that! regulate the production of interleukin cytokines.Interleukin-1 (IL-1) is well-established as one of the critical regulators of periodontal disease, and studies in non-human primates have shown that drugs specifically blocking IL-1 alone or IL-1 plus TNFa reduces tissue destruction even when the bacterial challenge is not reduced.

Inherent Health Brand of Genetic Tests

The Company's Weight Management Genetic Test helps take the guesswork out of finding an effective diet and exercise solution by revealing actionable steps to achieve weight goals based on genetics. The test provides new information beyond traditional assessments, so that nutritional intake and fitness routines can be tailored for improved, sustainable results. This test identifies five SNPs in four human genes: fatty acid binding protein 2 (FABP2); adrenergic receptor beta 2 (ADRB2 two variations); adrenergic receptor beta 3 (ADRB3); and peroxisome proliferator-activated receptor gamma (PPAR- ). These markers are involved in certain physiological pathways relating to body weight. Certain patterns of markers are associated with differential response to certain diet and exercise regimens.

The Company has conducted a number of studies that demonstrate a gene-diet interaction based on the multi-locus patterns . In the original study, 311 overweight/obese (body mass index, 27-40 kg/m2), nondiabetic, premenopausal, generally healthy women were randomly assigned for 12 months to either the Atkins-like ( low carbohydrate), Zone-like (low carbohydrate), LEARN-like (balanced), or Ornish-like (low fat) diets for the primary purpose of losing weight. The data collected in that study included dietary intake assessment (three unannounced 24-hour recalls for each time point administered by a dietitian and analyzed using NDS-R, University of Minnesota), anthropometric measures including weight, and related physiological variables, all collected at baseline, two, six, and 12 months.

Bone Health Genetic T! est

The Company's Bone Health Genetic Test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis. Although it typically starts later in life, early intervention can help prevent osteoporosis. Preventive measures can reduce the risk for bone loss and fractures, which in the case of vertebral fractures leads to a hunched over appearance. The test identifies a SNP in each of three genes involved in processes that affect bone; estrogen receptor alpha (ER1 Xba1), vitamin D receptor (VDR), and interleukin-1 (IL-1). Certain patterns of variations are associated with increased risk of spine fracture and/or low bone mineral density. The test can be used as an aid to making diet, exercise, and other lifestyle choices to maintain and improve bone health.

Nutritional Needs Genetics Test

The Company's Nutritional Needs Genetics Test is designed to identify DNA variations in genes crucial to B-vitamin metabolism and the ability to manage oxidative stress. Individuals with certain variations in these genes may be at increased risk for ineffective utilization of B-vitamins and potential for cell damage caused by oxidative stress, both of which can in some cases lead to increased risk for certain diseases. The test identifies the presence or absence of human genotypic markers methylenetetrahydrofolate reductase (MTHFR) and transcobalamin II (TCN2) involved in vitamin B metabolism and markers superoxide dismutase 2 (SOD2), glutathione S-transferase 1 deletions (GSTM1), paraoxonase 1 (PON1), X-ray repair cross complementing group 1 (XRCC1) in response to oxidative stress. Certain variations are associated with less efficient B-vitamin metabolism or reduced activity of endogenous anti-oxidant systems. The test may be used to aid individuals in deciding whether to supplement their diet with B vitamins and/or antioxidants.

Genetic Test Pipeline

The Company is focusing! its gene! tic test development efforts on programs, including Osteoarthritis Genetic Test. OA is the common adult joint disease, increasing in frequency and severity in all aging populations. The estimated U.S. prevalence is 20-40 million patients or five times that of rheumatoid arthritis. The Company's OA program plans to investigate whether interleukin gene variations together with several other inflammatory gene variations is associated with the occurrence of multi-joint OA for the development of a genetic risk assessment test.

Advisors' Opinion:

• [By Brian Marckx]

  Interleukin Genetics, Inc. (ILIU.PK) develops genetic tests focused on personal health. Through applied genetics research and scientific collaborations, the company has made significant progress in understanding how genetic make-up can affect an individual's predisposition and risk of suffering from certain diseases. Interleukin's research has specifically focused on a form of genetic variation called single nucleotide polymorphisms (SNP) and how it can have an impact on a person's health. The company has applied this knowledge in the development of genetic tests focused on areas such as weight management, cardiovascular health and periodontal disease. Interleukin sells its Inherent Health line of tests, which launched in 2009, to the consumer market and maintains a CLIA-certified lab at its headquarters in Waltham, Massachusetts, where consumers send test samples for processing.